Physician profile
Daniel Michael Alyesh
NPI 1780819979
$96,859.82
in general payments reported to CMS, 2019-2025
26 companies · $26K in 2025
The $26K reported for 2025 was more than what 91% of Clinical Cardiac Electrophysiology providers received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,155 · 2020: $4,723 · 2021: $3,265 · 2022: $16K · 2023: $25K · 2024: $21K · 2025: $26K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $41K · Travel and Lodging: $20K · Food and Beverage: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $40,601.50 |
| Travel and Lodging | $19,738.58 |
| Food and Beverage | $11,176.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $66,469.84 | 2019-2025 | Ensite, Tacticath Ablation Catheter, Sensor Enabled, Ensite Precision |
| Biosense Webster, INC. | $17,932.99 | 2019-2025 | Carto 3, Octaray Mapping Catheter, Qdot Micro Catheter |
| Sanofi-Aventis U.S. LLC | $4,568.34 | 2022-2024 | |
| Medtronic, INC. | $3,323.08 | 2021-2025 | Affera Mapping System, Pulseselect, Artic-L 3d Ti Spinal System With Tionic Technology |
| Boston Scientific Corporation | $1,676.76 | 2019-2025 | Farapulse, Watchman Access System, General - Therapies |
| Impulse Dynamics (USA) INC. | $516.41 | 2022-2025 | Optimizer, Optimizer |
| Atricure, INC. | $462.31 | 2024-2025 | Atriclip Laa Exclusion System, Epi-Sense Guided Coagulation System With Visitrax |
| Biotronik INC. | $281.86 | 2019-2024 | Acticor 7 Vr-T Dx, Amvia Edge |
| Pfizer INC. | $274.84 | 2019-2025 | |
| Amgen INC. | $249.78 | 2021-2025 | Repatha, Repatha |
| Medtronic Vascular, INC. | $231.14 | 2019-2020 | |
| Cardiva Medical, INC. | $141.65 | 2022-2023 | Cardiva Vascade Mvp Vvcs 6-12f, Cardiva Vascade 6/7f Vcs |
| E.R. Squibb & Sons, L.L.C. | $124.22 | 2023-2025 | Camzyos, Eliquis |
| Cordis US Corp. | $118.43 | 2025 | Mynx Control, Mynx Control Venous |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $79.27 | 2023-2024 | Lifevest |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.26 | 2022-2025 | Jardiance |
| Scpharmaceuticals INC. | $70.09 | 2025 | |
| Terumo Medical Corporation | $68.68 | 2019-2023 | Glidewire, Tr Band, Angio-Seal |
| Janssen Pharmaceuticals, INC | $44.74 | 2022-2024 | Xarelto |
| Kiniksa Pharmaceuticals International, Plc | $39.78 | 2024 | Arcalyst |
| Cardiovascular Systems INC. | $21.31 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.14 | 2025 | |
| Esperion Therapeutics, INC. | $19.19 | 2021 | |
| Amryt Pharma Holdings LTD | $17.90 | 2022 | |
| Merck Sharp & Dohme LLC | $15.74 | 2023 | Verquvo |
| Actelion Pharmaceuticals US, INC. | $13.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Alyesh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.